###### Strengths and limitations of this study

-   This is so far the largest study demonstrating feasibility of non-invasive ECG recording during a marathon race.

-   More than 100 experienced marathon runners underwent a unique serial blood sampling within 2--3 days before the marathon, directly after crossing the finish line and 1--2 days after the marathon race.

-   Cardiac MRI was performed in a subset of athletes with abnormal ECG findings and/or elevated troponin T values.

-   Serial echocardiography and a standardised exercise capacity testing would have allowed for a more comprehensive interpretation of the results.

Introduction {#s1}
============

Regular physical exercise has many health benefits: improving blood pressure control, insulin sensitivity and lipid profiles; it reduces overall mortality and disability[@R1] and the number of cardiovascular events.[@R2] Moreover, regular physical exercise also reduces the risk of certain cancers[@R4] and the number of mood disorders.[@R5] However, highly strenuous physical exercise may have a negative impact on cardiovascular health.[@R6] While marathon running has become a popular sport, cardiac arrest is rare but occurs in about 1:100 000 marathon runners, most commonly in those with hypertrophic cardiomyopathy or atherosclerotic coronary disease.[@R7] Available data on incidence of myocardial infarction after running a marathon are limited to case reports[@R8] and the prospective RACE Paris Registry,[@R9] but elevated levels of troponin---a sensitive biomarker of cardiac injury---were reported in a relevant subset of asymptomatic marathon runners.[@R10] Other potentially harmful effects of strenuous exercise, like right ventricular dysplasia and ventricular arrhythmia, have also been reported for triathletes and other ultra-endurance athletes.[@R13] Moreover, a meta-analysis of mostly retrospective and small case--control series as well as a recent cohort study indicated that intense endurance sport increases the long-term risk of atrial fibrillation (AF).[@R16] The European Heart Rhythm Association (EHRA) consortium has recently updated its recommendations regarding abnormal ventricular arrhythmias in endurance athletes and stated that a non-sustained ventricular tachycardia (nsVT) requires diagnostic evaluation for latent hypertrophic cardiomyopathy or ischaemic heart disease, especially if these occur under physical exercise.[@R18] However, there are so far very few publications regarding cardiac arrhythmias occurring during endurance sport.[@R19]

Herewith, we report the results of the prospective observational 'Berlin Beat of Running' study,[@R23] demonstrating feasibility of continuous ECG monitoring in 108 recreational endurance athletes during a marathon race. The pre-defined primary aim of the study was to analyse the frequency of cardiac arrhythmias and especially AF in a cohort of recreational endurance athletes. Pre-defined secondary aims were as follows: (1) to assess risk factors associated with cardiac arrhythmias in marathon runners, (2) to analyse the association between laboratory findings and the presence of cardiac arrhythmias during the race, and (3) to investigate whether marathon runners with elevated troponin levels (after the race) have MRI-detected myocardial scars suggestive of previous myocardial infarction.

Methods {#s2}
=======

Study design {#s2a}
------------

The Berlin Beat of Running study is a prospective, observational, investigator-initiated cohort study. The study design has been published in detail.[@R23] In short, all pre-registered participants were informed by the organisers of the marathon about the study, and they contacted the study personnel if they were interested. Participants aged 35--60 years with at least two marathon runs within the last 5 years and an average training of 40 km running per week were enrolled after giving written informed consent. Exclusion criteria included known cardiac disease or arrhythmia, prior stroke, tumour or infectious disease, severe liver or kidney disease, hyperthyroidism, pregnancy or lactation. Continuous ECG recording (using the CardioMem CM 4000 provided by GETEMED AG, Teltow, Germany) was started in 109 study participants up to 74 hours before the 38th BMW Berlin Marathon and continued throughout the entire race and for up to 58 hours afterwards. Laboratory assessment including high-sensitive troponin T (hsTnT) measurement with chemiluminescence immunoassays (Roche Diagnostics, Mannheim, Germany; cut-off 12 µg/L) was performed up to 74 hours before, within 30 min post-race and for up to 58 hours after the race. The study protocol is in accordance with the Helsinki declaration and was approved by the ethics committee of the Charité---Universitätsmedizin Berlin (EA4/042/11). The primary hypothesis was cardiac arrhythmias and especially AF are frequently found in experienced marathon runners. Therefore, the primary outcome is the number of marathon runners with newly diagnosed cardiac arrhythmias. The main secondary hypotheses were as follows: (1) there are predictable risk factors associated with cardiac arrhythmias in marathon runners, (2) pathological laboratory findings are (in part) associated with cardiac arrhythmias and (3) marathon runners with elevated troponin levels do not have MRI-detected myocardial scars suggestive of myocardial infarction. Follow-up information on medical history was assessed 1 year after the marathon.

MRI analysis {#s2b}
------------

A cardiac MRI after the race was offered to all study participants with either ST-T-segment deviation or hsTnT elevation. 3T MRI (Magnetom Tim Trio; Siemens AG) was performed using a phased array receiver coil during breath-holds gated to the electrocardiogram (Body Matrix-coil \#TATS; Siemens AG). Cine images of 3 long-axis and 14--18 short-axis views (slices of 4 mm) were created using a steady-state free precision technique.[@R24] Eight minutes after intravenous administration of 10--12 mL Gadovist (Bayer Schering Pharma AG) at a concentration of 1 mmol/mL, these views were repeated using a short inversion recovery sequence and continuously adjusting the inversion time.[@R25]

ECG analysis {#s2c}
------------

ECG monitoring was performed using a two-channel portable ECG recorder (CardioMem CM 4000; GETEMED AG). The cardiologists (AT, AW and WH) who analysed the ECG data were blinded for demographic, clinical or laboratory data. The five recorded leads were placed as follows in order to obtain two independent bipolar channels: left (1) and right (2) on the first intercostal space, right on the sixth intercostal space parasternal (3) and mid-clavicular line (4), and left ninth intercostal space mid-clavicular line (5). As there are no published recommendations on interpretation of a Holter ECG in athletes, we followed recommendations available for interpreting a 12-lead ECG in athletes[@R26] as well as recent EHRA guidelines on ventricular arrhythmias.[@R18] In line with this, we defined an abnormal ECG as presence of ST-T-segment deviation under physical exercise or arrhythmias. Low-pass filtering was set at 0.05 Hz in order to detect changes in the ST-T-segment. The ST segment was considered abnormal in the virtually artefact-free two-lead ECG if horizontal or down-sloping ≥1 mm occurred over the 60 ms after the J-junction (80 ms if the heart rate was \<120 beats per minute).[@R27] ST-segments were analysed in relation to the TP segment. Segments were analysed after recording of stable isoelectric TP segments in three consecutive beats. If single QRS complexes showed notching, slurring or fragmentation, QRS and ST intervals were excluded from further analysis. Episodes lasting more than 30 s preceded and followed by regular ECG recording were also considered abnormal. Drezner *et al* defined atrial arrhythmias as atrioventricular (AV) block grade IIb or III, AF or supraventricular tachycardia (SVT).[@R26] Ventricular arrhythmias were defined as nsVT of at least three premature ventricular complexes (PVCs) and a heart rate of ≥100 beats per minute.[@R18]

Statistical analysis {#s2d}
--------------------

In accordance with the sample size calculation, we planned to include 110 participants into the study.[@R23] For categorical data, absolute and relative frequencies were calculated using SPSS Statistics V.22. In the case of continuous variables with nearly normal distribution, we used the arithmetic mean, SD, minimal and maximal values, otherwise median, quartiles, and minimal and maximal values. The χ^2^ test was used to compare proportions for dichotomous outcomes between independent groups or to test independency of two dichotomous variables within a population. Outcomes in an ordinal scale or continuous outcomes were analysed using the t-test or the Mann-Whitney U test, depending on normality or non-normality of distribution. A p value of \<0.05 was considered to be statistically significant. In multivariate analysis, potential impact factors identified on a p\<0.05 level in univariate analysis were entered in a binary logistic regression model using backwards selection.

Results {#s3}
=======

Baseline data of study participants and feasibility of ECG recording {#s3a}
--------------------------------------------------------------------

Overall, 109 (99.1%) of 110 study participants took part, and 108 (98.2%) participants finished the 38th BMW Berlin Marathon 2011 in an average running time of 249±43 min. September 25, 2011, was a sunny day in Berlin and temperatures reached a maximum of 22°C. Data quality of long-term Holter ECG was sufficient to ensure assessment of arrhythmias and ST-T-segment deviations in 107 (98.2%) athletes, although motion and perspiration artefacts were present in the majority of athletes. In one athlete\'s device, a technical error occurred. Consistently wearing the ECG recorder on the upper arm using a carrier bag, no athlete reported problems in this regard. No athlete stopped wearing the ECG device prematurely. Baseline characteristics of these 107 participants are depicted in [table 1](#T1){ref-type="table"}. The median age of these 107 participants was 48 years; 23.9% were women. The cardiovascular risk profile was low. The participants had run a median of five marathon races within the last 5 years and a median of eight marathon races in total. Their average weekly running distance prior to the race was 40 km (IQR 30--50 km). In addition, athletes regularly went cycling (44.9%; n=48) or swimming (18.7%; n=20), respectively.

###### 

Baseline characteristics of the 107 participants of the 'Berlin Beat of Running' study who finished the marathon and who had evaluable ECG data

  ---------------------------------------- -------------------
  Age, mean, years, median (IQR)           48 (45--53)
  Female gender, % (n)                     24.3 (26)
  Body mass index, kg/m^2^, median (IQR)   23.4 (21.6--24.7)
  Hypertension, % (n)                      8.4 (9)
  Diabetes mellitus, % (n)                 0 (0)
  Heart failure, % (n)                     0 (0)
  Coronary artery disease, % (n)           0 (0)
  Hyperlipidaemia, % (n)                   2.8 (3)
  Current smoking, % (n)                   6.5 (7)
  Medication at enrolment                  
   Antiplatelet, % (n)                     0.9 (1)
   Oral anticoagulant, % (n)               0
   Beta-blocker, % (n)                     1.9 (2)
   Statin, % (n)                           1.9 (2)
   Antihypertensive, % (n)                 6.5 (7)
  ---------------------------------------- -------------------

Cardiac arrhythmias or ST-T-segment deviation during the marathon {#s3b}
-----------------------------------------------------------------

During the race, mean heart rate was 156.7±9.4 beats per minute. Minimum and maximum median heart rate were 133 (IQR 120--142) and 172 (IQR 166--177) beats per minute, respectively. We observed nsVT in 10 (9.4%) athletes ([figure 1](#F1){ref-type="fig"}), 2 (20%) of whom were women. In athletes with nsVTs, the median number of beats was 3 (IQR 3--5; range 3--9), median rate was 166 beats per minute (IQR 149--188; range 133--224) and median duration of the recorded nsVT was 1121 ms (IQR 919--1841; range 901--4400). We did not observe an AV block or an SVT. Persistent AF was found in one male patient (0.9%). Filtering of the monitors allowed interpretation of ST--T wave changes in fashion similar to a standard ECG. Exercise-induced ST-T-segment deviations occurred in eight (7.5%) study participants during the marathon race ([figure 2](#F2){ref-type="fig"}), two (25%) of whom were women. Characteristics of all athletes with ST-T-segment deviation are displayed in the online [supplementary file 1](#SP1){ref-type="supplementary-material"}. Intensity of ST-T-segment deviation in terms of ST level was −0.7 mV (IQR −0.8 to −0.3; range −0.9 to −0.16). ECG monitoring was prolonged for up to 54 hours (median 28 hours) after the marathon race. ST-T-segment deviations were not found in any athlete with ST-T-segment deviation during the marathon. One of these eight athletes also had nsVT. While four (3.7%) athletes reported palpitations during the marathon race, one had AF, one had a single nsVT (lasting nine beats) and another athlete had multiple supraventricular premature beats (62/hour). No athlete reported cardiac pain or dyspnoea. An abnormal ECG according to pre-defined criteria was found in 16.8% (n=18) of all participants. In univariate analysis, advanced age (p=0.004) and a longer marathon finishing time (p=0.009) were associated with abnormal ECG findings, while sex, cardiovascular risk profile, haematocrit post-race and the number of previous marathons were not. In multivariate analysis, advanced age remained significant (OR 1.11 per year, 95% CI 1.01 to 1.23) ([table 2](#T2){ref-type="table"}). In addition, athletes with an abnormal ECG had a higher frequency of PVCs (median 3.0 (IQR 1.0 to 12.3) vs 23.5 (IQR 10.0 to 44.0), p\<0.001) during the marathon race.

10.1136/bmjopen-2016-015798.supp1

![Non-sustained ventricular tachycardia in a well-trained 48-year-old male endurance runner without cardiovascular risk factors despite smoking.](bmjopen-2016-015798f01){#F1}

![ECG at rest (A) and exercise-induced ST-segment deviations (B) in a 60-year-old male endurance runner without cardiovascular risk.](bmjopen-2016-015798f02){#F2}

###### 

Cardiovascular risk profile and training status of recreational athletes with or without abnormal ECG findings, respectively

  ---------------------------------------------------------------------------------------------------------------------------------
                                              Normal\             Abnormal ECG        Univariate analysis   Multivariate analysis
                                              ECG                                                           
  ------------------------------------------- ------------------- ------------------- --------------------- -----------------------
  Age, years, median (IQR)                    48 (44--50)         54 (48--59)         0.004                 1.11 (1.01 to 1.23)

  Female gender, % (n)                        24.7 (22)           22.2 (4)            0.822                 

  Physical activity                                                                                         

   Marathon runs ≤5 years, median (IQR)       5 (4--10)           6 (4--7)            0.923                 

   Marathon runs total, n, median (IQR)       9 (5--18)           7 (6--14)           0.573                 

   Current running, km/week, median (IQR)     65 (50--80)         58 (50--70)         0.151                 

   Regular running, km/week, median (IQR)     40 (30--50)         40 (30--50)         0.409                 

   Present marathon time, min, median (IQR)   238 (215--268)      275 (229--326)      0.009                 1.44 (0.98 to 2.12)

   Haematocrit post-race, %, median (IQR)     0.44 (0.41--0.45)   0.43 (0.41--0.45)   0.711                 

  Body mass index, kg/m^2^, mean±SD           23.2±2.2            23.6±1.9            0.449                 

  Comorbidities                                                                                             

   Hypertension, % (n)                        6.7 (6)             16.7 (3)            0.166                 

   Hyperlipidaemia, % (n)                     2.2 (2)             2.8 (3)             0.438                 

   Current smoking, % (n)                     5.6 (5)             11.1 (2)            0.390                 
  ---------------------------------------------------------------------------------------------------------------------------------

ST-segment deviation, atrioventricular or ventricular arrhythmias (atrioventricular block grade IIb or III, triplets, non-sustained ventricular tachycardia, supraventricular tachycardia) or atrial fibrillation were regarded as abnormal findings. Values are expressed in % (n), mean±SD or median (IQR) as appropriate. Multivariate analysis was calculated in a binary logistic regression model using backwards selection.

\*p Value calculated by χ^2 ^test or Mann-Whitney U test, as appropriate.

Cardiac biomarkers and ECG changes during the marathon {#s3c}
------------------------------------------------------

At baseline, hsTnT was normal in all marathon runners (\<50 ng/L). Within minutes after the race was finished, hsTnT was elevated above 50 ng/L in 18 (16.8%) participants and median hsTnT was 3 ng/L (IQR 2--4; range 1--22). Median hsTnT values in 18 athletes with elevated hsTnT was 68.5 ng/L (IQR 62.8--85.5; range 50--216). Characteristics of all athletes with elevated hsTnT are displayed in the online [supplementary file 1](#SP1){ref-type="supplementary-material"}. In all athletes, median creatine kinase (CK) and CK-MB were 130 U/L (IQR 103--176) and 20 U/L (IQR 17--24) pre-marathon, respectively. Post-marathon CK was 336 (IQR 252--417) U/L and CK-MB was 35 (IQR 29--41) U/L.

Comparing athletes with an elevated hsTnT post--marathon with those without, we found no difference in age, sex, cardiovascular risk factors, training level or post-marathon CK-MB values ([table 3](#T3){ref-type="table"}). In runners with elevated hsTnT, we found more frequent ST-T-segment deviations (p\<0.0001) but no association with cardiac arrhythmias. In addition, elevated hsTnT was found in individuals with a longer marathon finishing time (p=0.040). Athletes with elevated hsTnT had a lower haematocrit compared with athletes without hsTnT elevation (p=0.003). In multivariate analysis, ST-T-segment deviation (OR 9.9, 95% CI 1.9 to 51.5) as well as haematocrit (OR 0.76%, 95% CI 0.62 to 0.92) remained statistically significant. Within 48 hours post-marathon, hsTnT was within normal range in 106 (99.1%) athletes; one athlete with no substantial ECG alterations during the marathon showed a persisting hsTnT elevation but normal 12-lead ECG post-marathon. Follow-up information was available for all 8 athletes with ST-T-segment deviation and for 8 out of 10 patients with nsVT during the race. None of the athletes reported a cardiovascular event within 1 year after the race.

###### 

Troponin T elevation post-marathon in the 107 athletes who finished the marathon race and who had evaluable ECG data

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
                                              Troponin T\            Troponin T\            Univariate analysis p Value\*   Multivariate analysis OR (95% CI)
                                              \<50 ng/L n=89         ≥50 ng/L n=18                                          
  ------------------------------------------- ---------------------- ---------------------- ------------------------------- -----------------------------------
  Age, years, median (IQR)                    48 (45--52)            49 (45--53)            0.605                           

  Female gender, % (n)                        21.3 (19)              38.9 (7)               0.114                           

  Body mass index, kg/m^2^, mean±SD           23 (22--25)            23 (22--25)            0.723                           

  Present marathon time, min, median (IQR)    236 (217--269)         268 (237--309)         0.040                           1.25 (0.83 to 1.87)

  Marathon runs ≤5 years, n, median (IQR)     6 (4--10)              5 (3--8)               0.327                           

  Marathon runs total, n, median (IQR)        9 (6--18)              7 (5--12)              0.147                           

  Regular weekly running, km, median (IQR)    40 (30--50)            40 (30--50)            0.791                           

  Coexisting hypertension, % (n)              9.0 (8)                5.6 (1)                0.632                           

  Hyperlipidaemia, % (n)                      3.4 (3)                0 (0)                  0.429                           

  ST-T-segment deviation, % (n)               3.4 (3)                27.8 (5)               \<0.0001                        9.9 (1.90 to 51.5)

  Arrhythmias, % (n)                          11.2 (10)              5.6 (1)                0.469                           

  Troponin pre-race, µg/L, median (IQR)       0.012 (0.012--0.012)   0.012 (0.012--0.012)   0.131                           

  Creatinine pre-race, mg/dL, median (IQR)    0.86 (0.81--0.96)      0.85 (0.77--0.97)      0.761                           

  Creatinine post-race, mg/dL, median (IQR)   1.27 (1.11--1.46)      1.34 (1.17--1.48)      0.424                           

  CK post-race, U/L, median (IQR)             333 (250--412)         350 (291--611)         0.263                           

  CK-MB post-race, U/L, median (IQR)          35 (28 to 41)          33 (29 to 52)          0.609                           

  Haematocrit post-race, %, median (IQR)      44 (42--46)            41 (39--44)            0.003                           0.76 (0.62 to 0.92)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are expressed in percent (n), mean±SD or median (IQR) as appropriate. Multivariate analysis was calculated in a binary logistic regression model using backwards selection.

\*p Value calculated by χ^2^ test or Mann-Whitney U test, as appropriate.

CK, creatine kinase.

Cardiac MRI in athletes with ST-T-segment deviation or elevated hsTnT {#s3d}
---------------------------------------------------------------------

Cardiac MRI was offered to all study participants with ST-T-segment deviation or hsTnT elevation. Five out of eight athletes with ST-T-segment deviation and hsTnT elevation as well as in 5 out of 18 athletes with hsTnT elevation but without ST-T-segment deviation underwent MRI within 10--42 days after the marathon race. Age, sex and cardiovascular risk factors did not differ in the 10 athletes undergoing cardiac MRI and the 14 athletes who did not undergo cardiac MRI. Cardiac MRI revealed no pathological findings for cardiac function, and there was no late gadolinium enhancement indicating myocardial fibrosis. Additional cardiac work-up was strongly recommended in all patients with pathological ECG findings.

Discussion {#s4}
==========

This is so far the largest study demonstrating feasibility of ECG recording during a marathon race, which may help counselling a subset of endurance athletes regarding exercise-associated complications. One main finding of the Berlin Beat of Running study is the unexpectedly high rate of abnormal ECG findings in 17% of recreational endurance athletes. Moreover, this is the first study reporting an association of transient ST-T-segment abnormalities during a marathon with elevated hsTnT levels after finishing the race. However, we cannot be sure that the observed ST-T-segment deviations are definitively based on silent ischaemia.

So far, there is limited data on ECG abnormalities during vigorous exercise.[@R28] Franco *et al* reported 'no arrhythmias' in 19 male athletes during a marathon,[@R21] while Aagaard *et al* found 'no ventricular arrhythmias' but AF in 2 (4%) of 49 male endurance runners during a 30-km race.[@R22] Luurila *et al* reported the presence of ventricular premature complexes in 33 (89%) of 37 recreational athletes during a ski marathon as well as ST-T-segment deviations in three (8%) of these middle-aged men.[@R20] Most recently, Grabs *et al* used a one-lead wireless ECG and reported premature atrial contractions but no arrhythmias in 20 male runners during a marathon race.[@R19] In our prospective study, 10 (9.4%) out of 107 recreational endurance athletes had a non-sustained ventricular arrhythmia during the marathon and one (0.9%) athlete had AF. In addition, ST-T-segment deviations ([figure 2](#F2){ref-type="fig"}) were detected in eight (7.5%) athletes. Advanced age was associated with abnormal ECG findings ([table 2](#T2){ref-type="table"}). According to the haematocrit, low hydration---potentially impacting on cardiac preload---was not linked to abnormal ECG findings. However, analysing athletes with ST-T-segment deviations, AF or ventricular arrhythmias, the underlying mechanisms of these pathological conditions may differ and the results of the multivariate analysis do not apply to a single condition.

Despite the fact that increased levels of physical activity were associated with a lower relative risk of myocardial infarction, 4% of patients with myocardial infarction report having performed strenuous exercise within hours before the cardiovascular event.[@R3] By using different cut-offs, transient elevations in the level of troponin T or troponin I have previously been reported in 18%--69% of marathon runners.[@R10] In the Berlin Beat of Running cohort, hsTnT was elevated in 18 (17%) out of 107 athletes but normalised within 48 hours in 17 (94%) athletes. Interestingly, elevation of hsTnT was not related to age, sex, training status, the cardiovascular risk profile or the presence of cardiac arrhythmias during the race, but was related to exercise-induced ST-T-segment deviation (p\<0.0001) and inversely correlated with the haematocrit (measured immediately after the race).

Cardiac MRI is now the gold standard for detecting myocardial damage[@R30] and myocardial oedema as well as decreased ventricular function after a marathon race.[@R31] We were not able to demonstrate late gadolinium enhancement as an indicator of permanent myocardial fibrosis in 10 experienced recreational athletes with ST-T-segment deviation or detected cardiac arrhythmia. This is in line with a previous study reporting no late gadolinium enhancement in 20 recreational athletes within 48 hours after a marathon race.[@R31] Interestingly, a transient cardiac oedema was reported in 17 (85%) out of 20 marathon runners,[@R31] but no correlation was reported between biomarkers and cardiac oedema. We are, however, unable to exclude a transient cardiac oedema in marathon runners because cardiac MRI was performed within 10--42 days after the marathon race.

Taken together, vigorous exercise can go along with transient troponin elevation, ST-T-segment alterations or nsVT in a fit and active population. However, athletes with ST-T-segment deviation or nsVT during the race did not report a cardiovascular event within 1 year afterwards. Thus, these findings are likely to be benign, but it was still recommended to rule out structural heart disease or obstructive coronary artery disease in these athletes. Our results strengthen the assumption that hsTnT elevation originates from the heart and not primarily from non-cardiac sources.[@R8] However, we are unable to draw final conclusions. Whether borderline cardiac damage by repetitive strenuous exercise could lead to permanent (potentially arrhythmogenic) cardiac remodelling is under debate.[@R6]

Focusing primarily on the feasibility of portable ECG monitoring and detection of ECG changes during the race, major limitations of the observational 'Berlin Beat of Running' study are the missing (serial) echocardiography or cardiac stress MRI, thus limiting the clinical significance of the observed ST-T-segment changes and elevated hsTnT levels. Furthermore, a normal cardiac MRI within days after the race does not completely rule out (transient) exercise-induced cardiac damage.[@R34] Since only one-fourth of all athletes were women and because of a potential selection bias during enrolment, the generalisability of our results is limited. Moreover, due to the limited number of endpoints observed, we believe that the results of the multivariate analysis should be interpreted with caution. Combining nsVT and ST-T-segment deviations for statistical analysis may have introduced an information bias. Unfortunately, it was impossible to assess the mean duration of ST-T-segment deviation in more detail, as ST-T-segment changes were present intermittently. Finally, exercise capacity testing would have allowed more accurate evaluation of training status.

Conclusion {#s5}
==========

ECG recording during a marathon race is feasible, which may be helpful in the diagnostic work-up of selected athletes. Cardiac arrhythmias or exercise-induced ST-T-segment deviations appear in a relevant subset of experienced recreational athletes during a marathon race and predominantly in older athletes. Marathon-induced ST-T-segment deviations were associated with elevated hsTnT values immediately after the race. Cardiac MRI detected no myocardial fibrosis by late gadolinium enhancement in a subset of these athletes.
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